{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:48:13Z","timestamp":1747154893900,"version":"3.40.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","annallergy.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.anai.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:10:05Z","timestamp":1724371805000},"page":"236-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["To stop or not to stop an asthma biologic, that is the question"],"prefix":"10.1016","volume":"133","author":[{"given":"Brianne S.","family":"Philipenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-4266","authenticated-orcid":false,"given":"Donald W.","family":"Cockcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2024.06.012_bib0001","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2024.04.031","article-title":"Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study","volume":"133","author":"Brightling","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2024.06.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/1744666X.2020.1686976","article-title":"Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis","volume":"15","author":"Cavalli","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2024.06.012_bib0006","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/annrheumdis-2017-211169","article-title":"Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial","volume":"76","author":"Bouman","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.anai.2024.06.012_bib0007","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.jaip.2020.06.056","article-title":"Effective omalizumab interval prolongation in the treatment of chronic urticaria","volume":"8","author":"Alizadeh Aghdam","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2024.06.012_bib0008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2024.06.012_bib0009","unstructured":"Global Initiative for Asthma \u2013 GINA. 2024 GINA main report: global strategy for asthma management and prevention. Accessed May 15, 2024. Available at: https:\/\/ginasthma.org\/2024-report\/"},{"issue":"5","key":"10.1016\/j.anai.2024.06.012_bib0010","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120624003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T02:40:17Z","timestamp":1729564817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120624003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1081120624003648"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2024.06.012","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To stop or not to stop an asthma biologic, that is the question","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2024.04.031","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}